RNAC Cartesian Therapeutics (RNAC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001453687
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
69
13F, latest reported quarter
Cartesian Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Cartesian Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jan 6, 2025.
- The trade is 7.3% of the 323,530 shares held after it.
- 2 other insiders sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Brunn Carsten sold about $162.1K of RNAC on Jan 6, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 69 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jan 6, 2025.
- The trade is 6.1% of the 58,820 shares held after it.
- 2 other insiders sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Miljkovic Milos sold about $24.4K of RNAC on Jan 6, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 69 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jan 6, 2025.
- The trade is 8.7% of the 121,220 shares held after it.
- 2 other insiders sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Davis Blaine sold about $72.2K of RNAC on Jan 6, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 69 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 12, 2024.
- The trade is 55.2% of the 54,366 shares held after it.
- No other insider bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BARABE TIMOTHY C bought about $205.8K of RNAC on Dec 4, 2025; 69 funds added in the latest 13F quarter.Context
- 48 earlier Form 4 trades (code P or S) here by this insider (48 buys), the last on Apr 10, 2025.
- +5.1% median (+13.8% mean) 90-day return after 27 previous buys.
- The trade is 0.1% of the 8,643,685 shares held after it.
- No other insider bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SPRINGER TIMOTHY A bought about $69.1K of RNAC on Apr 11, 2025; 69 funds added in the latest 13F quarter.84 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
69 funds bought in last quarter
more than 56% of Pharma & Biotech
Revenue
-99.0% year over year
below 91% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
16.1% of the float short (float per yahoo 2026-10-26) · 12.6 days to cover · settled 2026-09-30
more than 57% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RNAC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-30.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RNAC: institutional holders (13F)
13F holdings, latest reported quarter
2,254,619 sh
$23.5M
819,239 sh
$8.5M
650,000 sh
$6.8M
555,823 sh
$5.8M
368,429 sh
$3.8M
Congress trades in RNAC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RNAC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
RNAC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$139.5K position · as of 2026-05-31
0.9%
Janus Henderson Small Cap Growth Alpha ETF
$1.5M position · as of 2026-07-31
0.4%
Ultra-Small Company Market Fund
$338.6K position · as of 2026-06-30
0.2%
Select Biotechnology Portfolio
$2.8M position · as of 2026-05-31
0.1%
Clearwater Select Equity Fund
$221.3K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$459.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 1
0 active
5
Phase 2
3 active
1
Phase 3
1 active
1
Multi-phase
1 active
What changed recently
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach
2026-09-02 · Completion moved 2026-11-30 → 2026-12-30
Phase 3
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach
2026-09-02 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Dr. Brunn
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.3M
-$633.8K
$2.0M
-75%
n/a
2024
$7.3M
$6.5M
$2.8M
-39%
n/a
2023
$6.1M
$6.4M
$1.8M
-30%
n/a
2022
$4.3M
-$588.6K
$1.7M
-65%
n/a
2021
$3.7M
$4.3M
$1.3M
+8%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 69 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RNAC financials
Revenue growth
-99.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RNAC
| FY Dec 2025 | $2.8M |
| FY Dec 2024 | $38.9M |
| FY Dec 2023 | $26.0M |
| FY Dec 2022 | $110.8M |
| FY Dec 2021 | $85.1M |
| Jun 2026 | $0 |
| Mar 2026 | $78.0K |
| Dec 2025 | $947.0K |
| Sep 2025 | $452.0K |
| Jun 2025 | $298.0K |
| Mar 2025 | $1.1M |
| Dec 2024 | -$759.0K |
| Sep 2024 | $387.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-10,284%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RNAC
| FY Dec 2025 | -4,659% |
| FY Dec 2024 | -199.0% |
| FY Dec 2023 | -844.9% |
| FY Dec 2022 | +31.9% |
| FY Dec 2021 | -30.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -9,776% |
| Sep 2025 | -7,943% |
| Jun 2025 | +5,331% |
| Mar 2025 | -1,610% |
| Dec 2024 | n/a |
| Sep 2024 | -6,249% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$78.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RNAC
| FY Dec 2025 | -$79.4M |
| FY Dec 2024 | -$32.8M |
| FY Dec 2023 | -$51.4M |
| FY Dec 2022 | -$32.8M |
| FY Dec 2021 | -$61.5M |
| Jun 2026 | -$21.4M |
| Mar 2026 | -$22.2M |
| Dec 2025 | -$18.2M |
| Sep 2025 | -$16.9M |
| Jun 2025 | -$20.1M |
| Mar 2025 | -$24.2M |
| Dec 2024 | -$7.7M |
| Sep 2024 | $7.5M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity RNAC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.45x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt RNAC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.45x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity RNAC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +60.8% |
| FY Dec 2021 | -1,138% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -801.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-42.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RNAC
| FY Dec 2025 | -35.6% |
| FY Dec 2024 | -20.9% |
| FY Dec 2023 | -93.3% |
| FY Dec 2022 | +21.7% |
| FY Dec 2021 | -15.8% |
| Jun 2026 | -42.9% |
| Mar 2026 | -43.5% |
| Dec 2025 | -35.6% |
| Sep 2025 | -11.6% |
| Jun 2025 | -9.8% |
| Mar 2025 | -10.4% |
| Dec 2024 | -20.9% |
| Sep 2024 | -87.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital RNAC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-46.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RNAC
| FY Dec 2025 | -41.4% |
| FY Dec 2024 | -13.5% |
| FY Dec 2023 | -45.8% |
| FY Dec 2022 | +12.7% |
| FY Dec 2021 | -5.4% |
| Jun 2026 | -46.1% |
| Mar 2026 | -44.4% |
| Dec 2025 | -41.4% |
| Sep 2025 | -23.1% |
| Jun 2025 | -25.2% |
| Mar 2025 | -15.4% |
| Dec 2024 | -13.5% |
| Sep 2024 | -20.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RNAC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 847.50x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$95.2M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value RNAC
| FY Dec 2025 | $62.3M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $211.4M |
| Mar 2026 | $44.4M |
| Dec 2025 | $62.3M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-41.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield RNAC
| FY Dec 2025 | -42.3% |
| FY Dec 2024 | -7.2% |
| FY Dec 2023 | -1.6% |
| FY Dec 2022 | -0.6% |
| FY Dec 2021 | -0.5% |
| Jun 2026 | -25.7% |
| Mar 2026 | -47.5% |
| Dec 2025 | -42.3% |
| Sep 2025 | -25.9% |
| Jun 2025 | -16.5% |
| Mar 2025 | -11.8% |
| Dec 2024 | -7.2% |
| Sep 2024 | -14.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RNAC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.8M | $38.9M | $26.0M | $110.8M |
| Operating income | -$143.4M | -$43.9M | -$86.4M | $14.5M |
| Net income | -$130.3M | -$77.4M | -$219.7M | $35.4M |
| EPS (diluted) | -5.02 | -4.49 | -49.76 | 0.10 |
| Operating cash flow | -$73.9M | -$23.7M | -$51.2M | -$31.6M |
| Cash | $125.1M | $212.6M | $76.9M | $106.4M |
| Long-term debt | $0 | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
RNAC Stock Sonar score 5/7 axes
Find similar shapesCompareRNAC ranks highest on risk and compliance (57th percentile) and institutional and government (56th), and lowest on growth (4th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
